Intrexon | XON - Cash And Equivalent


Intrexon reported $9.34M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Amgen USD 13.99B 1.95B Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
MacroGenics USD 113.91M 47.39M Jun/2026
MannKind USD 52.93M 95K Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 299.52M 36.38M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026